lobbying_activities: 1383955
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1383955 | bdd722be-a021-4bc0-82e8-15e0d944d1cd | Q1 | APOTEX CORP. | 310973 | APOTEX CORP. | 2013 | first_quarter | PHA | S. 504, The Fair and Immediate Release of Generics Act, relating to market blockages caused by parked 180 day exclusivity periods S. 214, The Preserve Access to Affordable Pharmaceuticals Act, relating to the legality of "reverse payment" patent settlements Federal Trade Commission v. Actavis Supreme Court Case No. 12-416, relating to federal policy on "reverse payment" settlementsFederal legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing Actelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc., United States District Court for the District of New Jersey, case 1:12-cvi-05743-NLH-AMD, relating to federal legislation regarding the provision of brand drug products by brand manufacturers to generic manufacturers for development testing Federal legisation relating to the establishment of a federal track and trace system for pharmaceuticals Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2013-04-19T16:00:11.443000-04:00 |